Patents by Inventor Jon Wigginton

Jon Wigginton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT REGIMENS FOR EXON-20 INSERTION MUTANT EGFR CANCERS
    Publication number: 20230372346
    Abstract: Treatment regimens for exon 20 insertion mutant cancers with (S)—N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide (Compound 1).
    Type: Application
    Filed: September 7, 2021
    Publication date: November 23, 2023
    Applicant: CULLINAN PEARL CORP.
    Inventors: Briggs MORRISON, Jon WIGGINTON, David WITTER, Leigh ZAWEL, Myles CLANCY
  • Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
    Patent number: 10688180
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: June 23, 2020
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMA
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER
    Publication number: 20180117147
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Application
    Filed: September 13, 2017
    Publication date: May 3, 2018
    Inventors: Robert F. GRAZIANO, Ashok K. GUPTA, Su Young KIM, Jon WIGGINTON, Pascale ANDRE
  • COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT CANCER
    Publication number: 20180099045
    Abstract: Provided are methods for clinical treatment of cancer (e.g., advanced refractory solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-PD-1 antibody.
    Type: Application
    Filed: October 12, 2017
    Publication date: April 12, 2018
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Robert F. GRAZIANO, Ashok K. GUPTA, Su Young KIM, Jon WIGGINTON
  • Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
    Patent number: 9789182
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: October 17, 2017
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMA
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT CANCER
    Publication number: 20150290316
    Abstract: Provided are methods for clinical treatment of cancer (e.g., advanced refractory solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-PD-1 antibody.
    Type: Application
    Filed: October 2, 2013
    Publication date: October 15, 2015
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton
  • COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER
    Publication number: 20150283234
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Application
    Filed: October 23, 2013
    Publication date: October 8, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre